Gilead price target raised to $130 from $123 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the shares. Following recent physician checks and a “strong early launch,” the firm is raising its Livdelzi estimates, the analyst tells investors.